Kepler Cheuvreux Upgrades Bayer to 'Buy' with 25% Upside Target

Financial Analysts Project Strong Recovery for Bayer as Litigation Risks Stabilize and Earnings Forecasts Rise 10%

Three Key Facts

• Kepler Cheuvreux upgraded Bayer to “buy” with a €33 target price, suggesting 25% upside potential from current levels of €26.49
• Bayer’s earnings forecasts for 2026-2027 have been revised upward by 8-10%, with adjusted EBITDA expected to climb from €9.51 billion in 2024 to €14.16 billion by 2027
• €15 billion in litigation risk is already factored into share price, up from previous €10 billion estimate, with analysts believing worst-case scenarios are priced in

Introduction

Kepler Cheuvreux has upgraded Bayer’s stock to “buy,” marking a significant vote of confidence in the pharmaceutical and agricultural giant’s recovery trajectory. The upgrade comes as analysts highlight improved legal clarity surrounding ongoing litigation and stronger earnings projections that suggest the company has weathered its worst challenges.

According to Investing.com, this assessment follows a comprehensive review of Bayer’s litigation risks and operational performance. The move signals renewed institutional confidence in Bayer’s strategic direction, particularly as the company continues managing the substantial legal and financial burden inherited from its Monsanto acquisition.

Key Developments

Bayer shares responded positively to the upgrade news, climbing to over €27 on Tradegate in early trading. This represents the stock’s highest level since October 2024, though shares remain approximately 70% below pre-litigation levels.

The upgrade reflects analysts’ assessment that litigation risks are adequately reflected in current valuations. Kepler Cheuvreux notes that “a good chunk of the worst-case scenario” regarding legal challenges is already priced into shares. Investment banks HSBC and Kepler Cheuvreux both recommend buying shares with price targets reaching €33.

Bayer’s operational restructuring under CEO Bill Anderson has contributed to stabilized performance. The company has implemented cost discipline measures in its agricultural division and streamlined management structures, supporting improved earnings visibility.

Market Impact

Bayer’s stock performance reflects both challenges and recovery potential. The company shows year-to-date gains of 31.7%, with shares trading in a 52-week range between €18.87 and €30.45. Market capitalization stands at €26.0 billion, with average daily trading volume reaching €182.2 million.

The Pharmaceuticals division demonstrates strong momentum, posting 4% growth driven by exceptional performance from Nubeqa and Kerendia, which expanded 80% year-over-year. NUBEQA has achieved blockbuster status, exceeding €1 billion in annual sales and representing a key growth driver for the company.

However, the Crop Science division reported a 3% sales decline, primarily attributed to regulatory impacts. This mixed divisional performance underscores the importance of Bayer’s diversified revenue base across pharmaceuticals, healthcare, and agricultural chemicals.

Strategic Insights

Bayer’s financial projections paint an optimistic picture for the coming years. The company reported 2024 sales of €46.36 billion and projects growth to €50.42 billion in 2026 and €51.32 billion in 2027. These figures support analyst confidence in the company’s recovery trajectory.

Earnings metrics show substantial improvement potential. Adjusted earnings per share are forecast to rise from €4.41 in 2024 to €5.85 in 2027. Free cash flow projections indicate growth from €2.04 billion in 2024 to €4.44 billion in 2027, demonstrating improved cash generation capabilities.

The company’s pharmaceutical pipeline continues advancing with regulatory filings for key growth drivers including darolutamide, finerenone, and elinzanetant. The anticoagulant Asundexian represents another significant potential growth catalyst for future performance.

Expert Opinions and Data

Analysts have revised Bayer’s earnings forecasts upward by 8% to 10% above consensus for 2026 and 2027. These revisions reflect improved confidence in the company’s operational execution and strategic priorities implementation.

Dividend projections indicate substantial improvement, with expected growth from €0.41 per share in 2024 to €1.80 by 2027. This represents a dividend yield increase from 0.4% to 6.8%, suggesting management confidence in sustainable cash flow generation.

Wall Street analysts maintain a one-year price target averaging around $7.99 for US-listed Bayer AG shares. The convergence of positive analyst sentiment from multiple institutions reinforces the investment thesis supporting current valuations.

Industry observers note that litigation and ESG risk management remain essential considerations for pharmaceutical and agricultural companies. Bayer’s experience highlights the importance of comprehensive due diligence in major acquisitions and proactive legal risk management.

Summary

Kepler Cheuvreux’s upgrade to “buy” reflects growing analyst confidence that Bayer has adequately addressed its major challenges while positioning for sustainable growth. The company’s diversified portfolio, improving operational metrics, and robust pharmaceutical pipeline support the optimistic earnings revisions.

With litigation risks apparently factored into current valuations and operational performance showing signs of stabilization, Bayer presents what many analysts view as a compelling value proposition. The combination of attractive dividend prospects, strong pharmaceutical momentum, and strategic restructuring efforts underpins the positive investment thesis driving recent upgrades.